David Cohen

Connetics Corp. develops and commercializes dermatology products. The firm offers remedies for psoriasis in adults, eczema, seborrheic dermatitis, and acne. The company was founded in 1993 and is headquartered in Palo Alto, CA.

Vyteris, Inc. develops, manufactures and commercializes pharmaceutical products. It is engaged in the process of developing first active drug delivery patch to receive marketing clearance from the U.S. Food and Drug Administration. The drug delivery patch technology allows precise dosing, giving physicians and patients control in the rate, dosage and pattern of drug delivery that may result in considerable therapeutic, economical, and lifestyle advantages over existing methods of drug administration. The company was founded on July 19, 2000 and is headquartered in Fair Lawn, NJ.

Brickell Subsidiary, Inc. operates as a clinical-stage pharmaceutical company. It focuses on the development of differentiated, innovative drug therapies for the treatment of skin diseases. The firm specializes in Hyperhidrosis, Cutaneous T-Cell Lymphoma and Psoriasis areas. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in November 2009 and is headquartered in Boulder, CO.

Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY.

The New York Academy of Medicine (NYAM) is a leading advocate for innovation in public health. The non-profit company is based in New York, NY and has subsidiaries in the United States. For 176 years, NYAM has been at the forefront of promoting bold changes to the systems that perpetuate health inequities and prevent communities from achieving good health. NYAM's work includes innovative research, programs, and policy initiatives that value community input for maximum impact. NYAM's library is one of the most significant historical libraries in medicine and public health in the nation, with an extensive range of recommended resources available.

American Academy of Dermatology is the largest and most influential dermatology group in the United States. The private company is based in the United States and has subsidiaries in various locations. The American company provides resources on membership, education, practice management, publications, and clinical care for dermatologists. The company also offers information for patients and the public on skin, hair, and nail conditions. Elizabeth Usher has been the CEO of the company since 2019.

American Dermatological Association, Inc. recognizes, discusses and develops solutions for problems in the area of dermatologic health care, research and education. The company was founded in 1876 and is headquartered in Fort Lauderdale, FL.

Topica Pharmaceuticals, Inc. develops treatment for onychomycosis, or fungal infections of the nail and nail bed. Its prodycte, Luliconazole, a topical antifungal a topical antifungal agent used to tinea pedis. The company was founded in 2004 and is headquartered Los Altos, CA.